Ropsacitinib
Appearance
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H17N9 |
Molar mass | 383.419 g·mol−1 |
3D model (JSmol) | |
| |
|
Ropsacitinib (PF-06826647) is a drug which is an orally active, selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various autoimmune inflammatory conditions, primarily plaque psoriasis.[1][2][3]
See also
[edit]References
[edit]- ^ Martin G (February 2023). "Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors". Dermatology and Therapy. 13 (2): 417–435. doi:10.1007/s13555-022-00878-9. PMC 9884727. PMID 36592300.
- ^ Zhang K, Ye K, Tang H, Qi Z, Wang T, Mao J, et al. (April 2023). "Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors". Journal of Medicinal Chemistry. 66 (7): 4378–4416. doi:10.1021/acs.jmedchem.2c01800. PMID 36951608.
- ^ Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R (April 2024). "TYK2: an emerging therapeutic target in rheumatic disease". Nature Reviews. Rheumatology. 20 (4): 232–240. doi:10.1038/s41584-024-01093-w. PMID 38467779.